Skip to main content


Table 1 Demographic and clinical characteristics of 75 patients with early rheumatoid arthritis

From: The value of MRI examination on bilateral hands including proximal interphalangeal joints for disease assessment in patients with early rheumatoid arthritis: a cross-sectional cohort study

CharacteristicsEarly RA
N = 75
Female, n (%)53 (71)
Age, years, median (IQR)49 (38–59)
Disease duration, months, median (IQR)7 (3–12)
Core disease activity indexes
 28TJC, median (IQR)8 (5–13)
 28SJC, median (IQR)6 (3–9)
 PtGA, median (IQR)5.5 (4–8)
 PrGA, median (IQR)5 (4–7)
 ESR, mm/h, median (IQR)67 (38–81)
 CRP, mg/L, median (IQR)39 (13–63)
 RF positive rate, n (%)53 (71)
 ACPA positive rate, n (%)56 (75)
 DAS28-CRP, median (IQR)5.1 (4.2–6.1)
 SDAI, median (IQR)28 (20–41)
 CDAI, median (IQR)25 (17–34)
 HAQ-DI score, median (IQR)1.0 (0.3–1.8)
 Functional limitation, n (%)38 (51)
Radiographic assessment
 mTSS, median (IQR)8 (3–25)
 JSN subscore, median (IQR)1 (0–4)
 Erosion subscore, median (IQR)6 (2–22)
 Bone erosions, n (%)64 (85)
Prior therapy during 3 months before recruitment
 Treatment-naïve, n (%)44 (59%)
 Glucocorticoids, n (%)19 (25)
 Methotrexate, n (%)18 (24)
 Leflunomide, n (%)8 (11)
 Salazosulfadimidine, n (%)4 (5)
 hydroxychloroquine, n (%)6 (8)
 Biological DMARDs, n (%)3 (4)
 Chinese patent medicine, n (%)12 (16)
  1. IQR Interquartile range, 28TJC 28-joint tender joint count, 28SJC 28-joint swollen joint count, PtGA patient global assessment of disease activity, PrGA provider global assessment of disease activity, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, DAS28 disease activity score in 28 joints, SDAI simplified disease activity index, CDAI clinical disease activity index, HAQ-DI Health Assessment Questionnaire-Disability Index, mTSS modified total Sharp score, JSN joint space narrowing, DMARDs disease-modifying antirheumatic drugs
  2. Functional limitation was defined as HAQ-DI score ≥ 1 [17]
  3. Patients of treatment-naïve were defined as who had never taken any DMARDs or glucocorticoids before recruitment